MY103225A - Phenyl carbamate - Google Patents

Phenyl carbamate

Info

Publication number
MY103225A
MY103225A MYPI88000215A MYPI19880215A MY103225A MY 103225 A MY103225 A MY 103225A MY PI88000215 A MYPI88000215 A MY PI88000215A MY PI19880215 A MYPI19880215 A MY PI19880215A MY 103225 A MY103225 A MY 103225A
Authority
MY
Malaysia
Prior art keywords
phenyl carbamate
ethyl
carbamate
phenyl
salf
Prior art date
Application number
MYPI88000215A
Other languages
English (en)
Inventor
Enz Albert
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6322236&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MY103225(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MY103225A publication Critical patent/MY103225A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/40—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
    • C07C271/42—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/44—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
MYPI88000215A 1987-03-04 1988-03-03 Phenyl carbamate MY103225A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE3706914 1987-03-04

Publications (1)

Publication Number Publication Date
MY103225A true MY103225A (en) 1993-05-29

Family

ID=6322236

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI88000215A MY103225A (en) 1987-03-04 1988-03-03 Phenyl carbamate

Country Status (29)

Country Link
US (1) US5602176A (https=)
JP (3) JP2625478B2 (https=)
KR (1) KR0133686B1 (https=)
AT (1) AT394190B (https=)
AU (1) AU618949B2 (https=)
BE (1) BE1001467A3 (https=)
CA (1) CA1307003C (https=)
CH (1) CH675720A5 (https=)
CS (1) CS411091A3 (https=)
CY (1) CY1735A (https=)
DK (1) DK175762B1 (https=)
ES (1) ES2010527A6 (https=)
FI (1) FI89165C (https=)
FR (1) FR2611707B1 (https=)
GB (1) GB2203040C (https=)
GR (1) GR1000023B (https=)
HK (1) HK110093A (https=)
HU (1) HU201906B (https=)
IE (1) IE61714B1 (https=)
IL (1) IL85609A (https=)
IT (1) IT1219853B (https=)
LU (2) LU87150A1 (https=)
MY (1) MY103225A (https=)
NL (1) NL195004C (https=)
NZ (1) NZ223714A (https=)
PT (1) PT86875B (https=)
SA (1) SA93140384B1 (https=)
SE (1) SE8800731L (https=)
ZA (1) ZA881584B (https=)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU201906B (en) * 1987-03-04 1991-01-28 Sandoz Ag Process for producing phenyl-carbamate derivative and acid additional salts and pharmaceutical compositions containing them
AU2224195A (en) * 1994-04-15 1995-11-10 Masaomi Iyo Medicinal composition for treating tardive dyskinesia and utilization thereof
US6251938B1 (en) 1996-12-18 2001-06-26 Teva Pharmaceutical Industries, Ltd., Phenylethylamine derivatives
WO1998026775A1 (en) * 1996-12-18 1998-06-25 Teva Pharmaceutical Industries, Ltd. Phenylethylamine derivatives
ES2241064T3 (es) 1996-12-18 2005-10-16 Teva Pharmaceutical Industries, Ltd. Derivados de aminoindano.
GB9800526D0 (en) 1998-01-12 1998-03-11 Ciba Geigy Ag Organic compounds
US6316023B1 (en) * 1998-01-12 2001-11-13 Novartis Ag TTS containing an antioxidant
US6218383B1 (en) 1998-08-07 2001-04-17 Targacept, Inc. Pharmaceutical compositions for the prevention and treatment of central nervous system disorders
BR9914251A (pt) 1998-10-01 2001-06-19 Novartis Ag Formulações orais de liberação sustentada
US20040209849A1 (en) * 1998-11-27 2004-10-21 Sanochemia Pharmazeutika Aktiengesellschaft Use of effectors of the central cholinergic nervous system for treatment of delirium
JP2002531502A (ja) * 1998-12-11 2002-09-24 デイビス、ボニー 視床下部−下垂体−生殖腺軸変調に於けるアセチルコリンエステラーゼ阻害剤の使用
GB9923045D0 (en) * 1999-09-29 1999-12-01 Novartis Ag New oral formulations
US6534541B1 (en) * 1999-10-19 2003-03-18 Novartis Ag Treatment of ocular disorders
AU5702201A (en) * 2000-04-13 2001-10-30 Mayo Foundation Abeta<sub>42</sub> lowering agents
US20040010038A1 (en) * 2002-02-27 2004-01-15 Eran Blaugrund Propargylamino indan derivatives and propargylamino tetralin derivatives as brain-selective MAO inhibitors
CZ20023555A3 (cs) 2002-10-24 2004-01-14 Léčiva, A.S. Způsob výroby (-)-(S)-3-[1-(dimethylamino)ethyl]fenyl-N-ethyl-N-methylkarbamátu
KR100777904B1 (ko) * 2002-10-24 2007-11-28 메르츠 파마 게엠베하 운트 코. 카가아 1-아미노시클로헥산 유도체 및 아세틸콜린에스테라제 저해제를 포함하는 약학적 제품 및 이를 이용한 복합 치료
WO2004071431A2 (en) * 2003-02-05 2004-08-26 Myriad Genetics, Inc. Method and composition for treating neurodegenerative disorders
US7521481B2 (en) 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
KR20060040676A (ko) * 2003-07-11 2006-05-10 미리어드 제네틱스, 인크. 알츠하이머병을 치료하기 위한 약제학적 방법, 투약 방법및 제형
US7795307B2 (en) * 2003-10-21 2010-09-14 Colucid Pharmaceuticals, Inc. Carbamoyl esters that inhibit cholinesterase and release pharmacologically active agents
GB2409453A (en) * 2003-12-24 2005-06-29 Generics Process for the preparation of aminoalkyl phenylcarbamates
WO2006001877A2 (en) * 2004-04-13 2006-01-05 Myriad Genetics, Inc. Combination treatment for neurodegenerative disorders comprising r-flurbiprofen
AU2005241023A1 (en) * 2004-04-29 2005-11-17 Keystone Retaining Wall Systems, Inc. Veneers for walls, retaining walls and the like
EP1779867A4 (en) * 2004-07-01 2009-12-02 Eisai R&D Man Co Ltd MEANS FOR PROMOTING NERVE REVENERATION
WO2006020853A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
WO2006020850A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
WO2006020852A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
RU2393148C2 (ru) * 2004-11-08 2010-06-27 Эмкюр Фармасьютикалз Лимитед Способ получения (s)-3-[(1-диметиламино)этил]-фенил-n-этил-n-метил-карбамата
GB0507298D0 (en) 2005-04-11 2005-05-18 Novartis Ag Organic compounds
KR20080039876A (ko) * 2005-07-22 2008-05-07 미리어드 제네틱스, 인크. 높은 약물 충진 제형 및 투여형
ES2267399B1 (es) 2005-08-04 2008-02-01 Ragactives, S.L. Procedimiento para la obtencion de carbamatos de fenilo.
JP5116679B2 (ja) 2005-09-15 2013-01-09 株式会社ソニー・コンピュータエンタテインメント 強度のコンピュータ画像および音声処理、ならびにコンピュータプログラムとインタフェースするための入力装置
TWI389709B (zh) * 2005-12-01 2013-03-21 Novartis Ag 經皮治療系統
ES2632638T3 (es) * 2005-12-09 2017-09-14 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Ladostigilo de baja dosis para el tratamiento de la deficiencia cognitiva
TW200744576A (en) * 2006-02-24 2007-12-16 Teva Pharma Propargylated aminoindans, processes for preparation, and uses thereof
US7767843B2 (en) * 2006-03-02 2010-08-03 Apotex Pharmachem Inc. Process for the preparation of phenylcarbamates
EP2046119A2 (en) * 2006-07-07 2009-04-15 Myriad Genetics, Inc. Treatment of psychiatric disorders
CA2661009A1 (en) * 2006-08-17 2008-02-21 Alembic Limited Improved process for the preparation of rivastigmine
WO2008037433A1 (en) 2006-09-29 2008-04-03 Synthon B.V. Process for making aminoalkylphenyl carbamates and intermediates therefor
AU2007309390A1 (en) 2006-10-27 2008-05-02 Medivation Neurology, Inc. Methods and combination therapies for treating Alzheimer's disease
EP1942100A1 (en) * 2007-01-04 2008-07-09 Krka Tovarna Zdravil, D.D., Novo Mesto Amorphous and crystalline forms of rivastigmine hydrogentartrate
AU2008214380A1 (en) * 2007-02-02 2008-08-14 Colucid Pharmaceuticals, Inc. Compounds that inhibit cholinesterase
US8013181B2 (en) * 2007-04-10 2011-09-06 Dr. Reddy's Laboratories Limited Preparation of rivastigmine and its salts
WO2008124969A1 (en) * 2007-04-16 2008-10-23 Topharman Shanghai Co., Ltd. Preparation method of rivastigmine and its intermediates
US7884121B2 (en) * 2007-06-11 2011-02-08 Apotex Pharmachem Inc. Process for the preparation of phenylcarbamates
JP2010533717A (ja) * 2007-07-18 2010-10-28 コルシド・ファーマシューティカルズ・インコーポレイテッド 覚醒を促進する方法
US8593728B2 (en) * 2009-02-19 2013-11-26 Toyota Motor Engineering & Manufacturing North America, Inc. Multilayer photonic structures
US20090082436A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched rivastigmine
CN101910110B (zh) * 2008-01-10 2013-05-22 上海医药工业研究院 利凡斯的明的制备方法、其中间体以及中间体的制备方法
US8420846B2 (en) 2008-08-25 2013-04-16 Jubilant Life Sciences Limited Process for producing (S)-3-[(1-dimethylamino)ethyl] phenyl-N-ethyl-N-methyl-carbamate via novel intermediates
US20100087768A1 (en) * 2008-10-02 2010-04-08 Forlano Paula Transdermal drug delivery system for liquid active ingredient
GB0823554D0 (en) 2008-12-24 2009-01-28 Novartis Ag Process for the preparation of optically active compounds using transfer hydrogenation
CN101823970B (zh) * 2009-03-03 2013-05-08 江苏恩华药业股份有限公司 卡巴拉汀及其中间体的合成方法
ES2670227T3 (es) 2009-12-22 2018-05-29 Luye Pharma Ag Sistema terapéutico transdérmico para la administración de rivastigmina o sus derivados
US10076502B2 (en) 2009-12-22 2018-09-18 Luye Pharma Ag Transdermal therapeutic system for administering rivastigmine or derivatives thereof
ES2363395B1 (es) * 2010-01-20 2012-02-23 Farmalider, S.A. Composición farmacéutica l�?quida de rivastigmina o de una de sus sales de adición de �?cido para la administración por v�?a oral.
EA202092673A3 (ru) * 2010-02-09 2021-05-31 Дзе Джонс Хопкинс Юниверсити Способы и композиции для улучшения когнитивной функции
BR112012024708A2 (pt) 2010-03-29 2016-06-07 Novartis Ag composição de compostos orgânicos
WO2011151669A1 (en) 2010-06-02 2011-12-08 Jubilant Life Sciences Limited Process for producing enantiomerically enriched isomer of 3-(1-aminoethyl) phenyl derivative and employing the same to produce rivastigmine or its pharmaceutically acceptable salt
WO2011151359A1 (en) 2010-06-02 2011-12-08 Noscira, S.A. Combined treatment with a cholinesterase inhibitor and a thiadiazolidinedione derivative
DK2582799T3 (en) 2010-06-17 2018-02-12 Codexis Inc BIOCATALATORS AND PROCEDURES FOR THE SYNTHESIS OF (S) -3- (1-AMINOETHYL) -PHENOL
EP3034079B1 (en) 2010-11-15 2018-01-10 Agenebio, Inc. Pyridazine derivatives, compositions and methods for treating cognitive impairment
DK2468274T3 (en) 2010-12-14 2015-08-31 Acino Ag Transdermal therapeutic system for administration of an active substance
CN102786441B (zh) * 2011-05-18 2013-11-13 浙江海正药业股份有限公司 利凡斯的明的制备方法、其中间体以及中间体的制备方法
BR112013029945A2 (pt) 2011-05-20 2017-01-31 Sk Chemicals Co Ltd emplastro contendo rivastigmina
AR082640A1 (es) * 2011-08-25 2012-12-19 Amarin Technologies S A Un dispositivo para la administracion transdermal de compuestos alcalinos susceptibles a la degradacion en su forma no salificada
JP6102739B2 (ja) 2011-08-31 2017-03-29 東洋インキＳｃホールディングス株式会社 貼付剤
CN103073456B (zh) * 2011-10-26 2014-03-19 连云港润众制药有限公司 重酒石酸卡巴拉汀中间体的制备方法
EP2594261A1 (en) 2011-11-18 2013-05-22 Labtec GmbH Composition for transdermal administration of rivastigmine
WO2013142339A1 (en) 2012-03-23 2013-09-26 Novartis Ag Transdermal therapeutic system and method
ES2449215B1 (es) * 2012-09-17 2014-07-14 Galenicum Health S.L. Solución oral de (S)-3-[1-(dimetilamino)etil]fenil N-etil-N-metilcarbamato
KR20140038237A (ko) 2012-09-20 2014-03-28 에스케이케미칼주식회사 리바스티그민의 안정성이 개선된 의약품
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
CN103896787A (zh) * 2012-12-26 2014-07-02 江苏康倍得药业有限公司 一种卡巴拉汀前体[1-(3-甲氧基苯基)乙基]二甲胺的制备方法
WO2014111790A2 (en) 2013-01-15 2014-07-24 Zydus Technologies Limited Stable transdermal pharmaceutical drug delivery system comprising rivastigmine
AU2014228512A1 (en) 2013-03-15 2015-10-01 Agenebio, Inc. Methods and compositions for improving cognitive function
WO2014144663A1 (en) 2013-03-15 2014-09-18 The Johns Hopkins University Methods and compositions for improving cognitive function
CN103319374B (zh) * 2013-06-09 2015-04-22 无锡佰翱得生物科学有限公司 一种(s)-卡巴拉汀的不对称合成方法
AU2014307803A1 (en) 2013-08-16 2016-03-10 Universiteit Maastricht Treatment of cognitive impairment with PDE4 inhibitor
EP3083569B1 (en) 2013-12-20 2022-01-26 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
CA2986598C (en) 2015-05-22 2023-09-26 Agenebio, Inc. Extended release pharmaceutical compositions of levetiracetam
JP6987384B2 (ja) 2015-06-19 2021-12-22 エージンバイオ， インコーポレイテッド ベンゾジアゼピン誘導体、組成物、および認知障害を処置するための方法
US11505555B2 (en) 2016-12-19 2022-11-22 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US20180170941A1 (en) 2016-12-19 2018-06-21 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
US11414425B2 (en) 2018-06-19 2022-08-16 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
KR20200035359A (ko) 2018-09-26 2020-04-03 캐딜라 파마슈티클즈 리미티드 리바스티그민 제조용 중간체의 합성
WO2024039886A1 (en) 2022-08-19 2024-02-22 Agenebio, Inc. Benzazepine derivatives, compositions, and methods for treating cognitive impairment
WO2025038382A1 (en) 2023-08-11 2025-02-20 Momentive Performance Materials Inc. Pharmaceutical adhesive compositions

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4469700A (en) * 1981-06-19 1984-09-04 Lowell M. Somers Benzoylecgonine or benzoylnorecgonine as active agents for the treatment of rheumatoid arthritis
IL74497A (en) * 1985-03-05 1990-02-09 Proterra Ag Pharmaceutical compositions containing phenyl carbamate derivatives and certain phenyl carbamate derivatives
HU201906B (en) * 1987-03-04 1991-01-28 Sandoz Ag Process for producing phenyl-carbamate derivative and acid additional salts and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
KR880011088A (ko) 1988-10-26
IL85609A (en) 1992-07-15
SA93140384B1 (ar) 2006-04-04
CA1307003C (en) 1992-09-01
NL195004C (nl) 2003-11-04
GB2203040C (en) 2014-07-30
HU201906B (en) 1991-01-28
JPH09165362A (ja) 1997-06-24
LU87150A1 (fr) 1988-11-17
AT394190B (de) 1992-02-10
FI880972A0 (fi) 1988-03-02
ATA55188A (de) 1991-08-15
DK112588D0 (da) 1988-03-02
JP2625478B2 (ja) 1997-07-02
JP2859225B2 (ja) 1999-02-17
IL85609A0 (en) 1988-08-31
FI880972L (fi) 1988-09-05
GB2203040B (en) 1990-10-24
FR2611707B1 (fr) 1990-04-20
AU618949B2 (en) 1992-01-16
JPS63238054A (ja) 1988-10-04
FI89165B (fi) 1993-05-14
GB8804888D0 (en) 1988-03-30
NL8800436A (nl) 1988-10-03
IT1219853B (it) 1990-05-24
HK110093A (en) 1993-10-29
SE8800731A0 (sv) 1988-09-05
US5602176A (en) 1997-02-11
PT86875B (pt) 1992-05-29
HUT49325A (en) 1989-09-28
GR880100125A (en) 1989-01-31
SE8800731D0 (sv) 1988-03-02
DK175762B1 (da) 2005-02-14
KR0133686B1 (ko) 1998-04-21
IT8847693A0 (it) 1988-03-04
CY1735A (en) 1994-06-03
FI89165C (fi) 1993-08-25
IE61714B1 (en) 1994-11-30
DK112588A (da) 1988-09-05
BE1001467A3 (fr) 1989-11-07
JPH09118617A (ja) 1997-05-06
PT86875A (pt) 1988-04-01
LU90297I2 (fr) 1998-12-07
NZ223714A (en) 1994-05-26
CH675720A5 (https=) 1990-10-31
IE880583L (en) 1988-09-04
AU1255488A (en) 1988-09-08
ZA881584B (en) 1989-11-29
GB2203040A (en) 1988-10-12
FR2611707A1 (fr) 1988-09-09
NL195004B (nl) 2003-07-01
ES2010527A6 (es) 1989-11-16
CS411091A3 (en) 1992-12-16
SE8800731L (sv) 1988-09-05
GR1000023B (el) 1990-01-31

Similar Documents

Publication Publication Date Title
MY103225A (en) Phenyl carbamate
MY105121A (en) Pharmaceutical composition for systemic transdermal administration.
PH31617A (en) Novel thienylcarboxylates of amino alcohols, theirquaternary products and use of these compounds.
IL74497A0 (en) Pharmaceutical compositions and phenyl carbamate derivatives
YU211087A (en) Process for obtaining new n-substituted benzimidazolic derivatives
JO1502B1 (en) New pharmacy vehicles
IL94433A0 (en) Aminophenol derivatives,their preparation and pharmaceutical compositions containing them
EP0160501A3 (en) Sustained release intranasal formulation and method of use thereof
HUT42447A (en) Process for preparing novel benzol derivatives and pharmaceutical compositions comprising the same as active substance
FI922815L (fi) Menetelmä uusien farmaseuttisesti aktiivisten D-vitamiinianalogien valmistamiseksi
PT90308A (pt) Processo para a preparacao de composicoes farmaceuticas contendo azelastina com libertacao controlada da substancia activa
IT1243193B (it) Composizioni farmaceutiche orali a base di melatonina
HUT46660A (en) Process for producing 3-alkoxy-2-amino-propyl-amines and pharmaceutical compositions comprising the same as active ingredient
IL78604A (en) Process for the preparation of homogeneous,pure alpha-interferon,alpha-interferon produced thereby and pharmaceutical compositions containing it
IL85189A (en) Beta-alkyl substituted melatonins,their preparation and pharmaceutical compositions containing them
PT83253A (en) Process for preparing p-acylaminobenzamides
CA976970A (en) N-((diamino, 2&#39;,4&#39; aza 3&#39;) phenyl)-benzoquinones imines
GR3005495T3 (https=)
IT1247508B (it) Composizioni farmaceutiche contenenti l&#39;estere 4-(2 metilamminoetil)- 1,2- fenilenicodell`acido 2-metilpropanoico per il trattamento della neurootticopatia glaucomatosa
JO1531B1 (en) New near-compounds
DE3573724D1 (en) Use of 1,8,9-triacetoxy-anthracene as the active ingredient in the preparation of an antitumoral pharmaceutical compound
IT8723007A0 (it) Composizioni farmaceutiche per uso orale ad attivita&#39; sequestrante degli acidi biliari contenenti colestiramina quale principio attivo, e procedimento per prepararle